Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Michael E. Kelly MD, PhD
Associate Professor
Department of Pediatrics
Division of Hematology/Oncology

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

CITIZENSHIP:  USA

EDUCATION:
6/1980 - 5/1985 Biological Sciences, University of Cincinnati, Cincinnati, OH
9/1985 - 6/1993 Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH
1992 PhD, University of Cincinnati College, Developmental Biology Program, Cincinnati, OH
1993 MD, University of Cincinnati College of Medicine, Cincinnati, OH

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
7/1993 - 6/1994 Intern, Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO
7/1994 - 6/1996 Resident, Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO
7/1996 - 6/1999 Fellow, Pediatrics, Hematology/Oncology, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO

FACULTY APPOINTMENTS:
9/1999 - 8/2001 Instructor, Pediatrics, Hematology and Oncology, Washington University School of Medicine, St. Louis, MO
9/2001 - 12/2001 Instructor, Pediatrics, Hematology and Oncology, Saint Louis University School of Medicine, St. Louis, MO
1/2002 - 6/2005 Assistant Professor, Pediatrics, Hematology and Oncology, Saint Louis University School of Medicine, St. Louis, MO
7/2005 - 6/2008 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
7/2008 - Present Associate Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
1/2002 - 5/2005 Member of the Biomedical Institutional Review Board, Saint Louis University School of Medicine, Cardinal Glennon Children’s Hospital, St. Louis, MO
6/2003 - 5/2005 Program Director, Pediatric Hematopoietic Progenitor Cell Transplantation, Saint Louis University School of Medicine, Cardinal Glennon Children’s Hospital, St. Louis, MO
3/2009 - 11/2011 Member, Section Leadership Group, Department of Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
7/2010 - Present Director, Pediatric Cancer Clinical Trials Office, Department of Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
1/2011 - Present Member, Leadership Committee, Cancer Center, Medical College of Wisonsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
9/2005 - 6/2012 Fellowship Program Director, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
6/2006 - 7/1/2010 Program Director, Pediatric Autologous Hematopoietic Cell Transplantation, Children's Hospital of Wisconsin, Milwaukee, WI
3/2008 - Present Director, Cancer Program, Children's Hospital of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
8/2008 - Present Institutional Principal Investigator, Children's Hospital of Wisconsin, Midwest Children's Cancer Center, Children's Oncology Group, Milwaukee, WI
7/2010 - Present Director, Pediatric Cancer Clinical Trials Office, Department of Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
8/2011 - Present Institutional Principal Investigator, Children's Hospital of Wisconsin, Children's Oncology Group - Phase 1 and Pilot Consortium, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
1999 - 2001 Attending Physician, Pediatrics, Hematology/Oncology, St. Louis Children’s Hospital, St. Louis, MO
2001 - 2005 Attending Physician, Pediatrics, Hematology/Oncology, Cardinal Glennon Children's Hospital, St. Louis, MO
7/2005 - Present Attending Physician, Pediatrics, Hematology/Oncology/BMT, Children's Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Diplomate, National Board of Medical Examiners
1994
None
American Board of Pediatrics
2001
1/2010
American Board of Pediatrics - Hematology-Oncology
2002
2014
 
Licensure
Number Issue DateExpiration
Wisconsin Licensure
#48155-020
2005
10/31/2015
 
AWARDS AND HONORS:
1991 - 1993 Marion Merrell Dow Scholar
1997 - 1998 St. Louis Children's Hospital Cancer Fund Research Fellow
2006 - 2007 Selected to attend the UW-Milwaukee & Medical College of Wisconsin Faculty Leadership Development Program
2008 - 2009 Children's Specialty Group Leader Development Program
2010 Southeast Wisconsin's Best Doctors
2010 Cambridge Who's Who
2011 Best Doctor's in America
2011 Professional of the Year Representing Pediatric Hematology & Oncology, Cambridge Who's Who

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Academy of Pediatrics
Pediatric Blood and Marrow Transplant Consortium
American Society of Hematologists
Children's Oncology Group Full Member
American Society of Pediatric Hematologists and Oncologists
Hemangioma Investigator Group
American Society of Clinical Oncology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
Pediatric Blood and Cancer
Journal of Clinical Oncology
Journal of Pediatric Hematology/Oncology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
6/2008 - Present Co-Director, Pediatric BioBank and Analytical Tissue Core, Children's Hospital of Wisconsin
6/2010 - Present Member, Search Committee for Chief of Pediatric Hematology, Oncology and Bone Marrow Transplant and MACC Fund Professor, Medical College of Wisconsin
1/2011 - Present Member, Cancer Center Leadership Committee, Medical College of Wisconsin

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2009 - Present Invited Research Grant Reviewer, St Baldrick’s Foundation

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Children's Oncology Group Institutional Participation
Source:
National Cancer Institute
Role:
Principal Investigator
PI:
Michael E. Kelly
Dates:
8/2009 - Present
Direct Funds:
$59,010 (Reimbursement for salary 20% support of institutional principle investigator and administrative costs)
 
Title:
Children's Oncology Group Institutional Participation
Source:
National Cancer Institute
Role:
Principal Investigator
PI:
Michael E. Kelly
Dates:
8/2009 - Present
 
Title:
Treatment for Acute Lymphoblastic Leukemia using Erwinase Erwinia Chrysanthemi L-Asparaginase for Injection
Source:
EUSA Pharmaceutical
Role:
Institutional Principal Investigator
PI:
Michael E. Kelly
Dates:
4/1/2010 - 3/31/2018
 
Title:
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Leukemia
Source:
Cephalon
Role:
Institutional Principal Investigator
PI:
Michael E. Kelly
Dates:
11/2010 - Present
 
Title:
Children’s Oncology Group Phase 1 Institutional Participation
Role:
Principal Investigator
PI:
Michael E. Kelly
Dates:
8/2011 - Present
 
Title:
Children's Oncology Group Phase 1 and Pilot Consortium
Source:
National Cancer Institute
Role:
Institutional Principal Investigator
PI:
Michael E. Kelly
Dates:
8/2011 - Present
 
Title:
1000EUSA12: An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi) Following Allergy to Native E. Coli Asparaginase (Elspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (A Phase 2 Clinical Trial)
Source:
Jazz Pharmaceutical
Role:
Institutional Principle Investigator
Dates:
12/2012 - Present
 
Non-Peer Review
Title:
Infrastructure to Facilitate Clinical and Translational Research in Pediatric Oncology at Children's Hospital of Wisconsin
Source:
Midwest Athletes against Childhood Cancer (MACC Fund)
Role:
Principal Investigator
Dates:
7/2008 - 6/2013
Direct Funds:
$5,000,000
 
Title:
Preventing Obesity in Children Diagnosed with Acute Lymphoblastic Leukemia: A Pilot Study
Source:
Circle of Hope
Role:
Co-PI
PI:
Richard Tower, II
Dates:
7/1/2012 - 12/31/2013
Direct Funds:
$50,000 (This grant is a prospective, interventional pilot trial testing dietary and exercise interventions in preventing obesity in children with ALL undergoing treatment)
 
Pending
Peer Review
Title:
Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immune Deficiency
Source:
R34, National Institute of Health
Role:
Co-PI with John Routes
 
Title:
MMP Inhibitors for Treatment of Artery-Vein Malformations
Source:
X02; NIH PAR-12-203 “A pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules
Role:
Co-PI with Ramani Romschandran
 
Prior
Peer Review
Title:
Increasing Blood and Cord Blood Donations in Blacks
Source:
National Institute of Diabetes and Digestive and Kidney Diseases.
Role:
Institutional Principal Investigator
PI:
Michael DeBaun, M.D.
Dates:
9/20/2002 - 6/30/2007
Direct Funds:
$750,000
 
Title:
Immune Suppression of Infants Treated with Oral Corticosteroids for Infantile Hemangiomas
Source:
Society for Pediatric Dermatology
Role:
Co-Investigator
PI:
Beth Drolet
Dates:
2006 - 2007
Direct Funds:
$15,000
 
Title:
Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas
Source:
Bleser Family Foundation (through Children's Hospital Foundation)
Role:
Principal Investigator with Beth Drolet
Dates:
12/2007 - 12/2010
Direct Funds:
$150,000
 
Title:
Immune Suppression of Infants Treated with Oral Corticosteroids for Infantile Hemangiomas
Source:
MCW
Role:
Co-Investigator with William Grossman
PI:
Beth Drolet, M.D.
Dates:
2007 - 2008
Direct Funds:
$12,500
 
Title:
Vincristine versus Steroids for the Treatment of Infantile Hemangiomas
Source:
Milwaukee Foundation
Role:
Principal Investigator with Beth Drolet (15% effort)
Dates:
2007 - 2008
Direct Funds:
$50,000
 
Title:
Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisilone vs. Vincristine in the Treatment of Infantile Hemangiomas
Source:
R01, Food and Drug Administration (FDA)
Role:
Principal Investigator with Beth Drolet (15% effort)
PI:
Michael E Kelly and Beth Drolet
Dates:
2007 - 2012
Direct Funds:
$926,586
 
Title:
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Leukemia
Source:
Cephalon
Role:
Institutional Principle Investigator
Dates:
11/2010 - 1/2012
 
Title:
Interdisciplinary Workshop on Vascular Anomalies Associated with Coagulopathy
Source:
NIH/NIAMS & NHLBI (R13)
Role:
Principal Investigator with Beth Drolet
PI:
Michael E. Kelly
Dates:
7/1/2011 - 6/30/2012
Direct Funds:
$57,137
 
Title:
Interdisciplinary Workshop on Vascular Anomalies Associated with Coagulopathy
Source:
NIH/NIAMS & NHLBI (R13)
Role:
Co-PI with Beth Drolet
Dates:
7/1/2011 - 1/1/2013
Direct Funds:
$57,137
 
Title:
Infrastructure for Phase 1 Studies at Midwest Children’s Cancer Center
Source:
St. Baldrick's Foundation
Role:
Principal Investigator
Dates:
1/1/2012 - 12/31/2012
Direct Funds:
$50,000
 
Title:
Use of a PD-1 Fusion Protein to Improve St. Baldrick’s Summer Fellowship - T-Cell Responses after Cancer Immunotherapy
Source:
St. Baldrick's Foundation
Role:
Principal Investigator
PI:
Michael E. Kelly
Dates:
5/31/2012 - 8/30/2012
Direct Funds:
$5,000
 
Non-Peer Review
Title:
Safety and Feasibility Trial of Oral Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults
Source:
Rebecca Slye Endowment Fund (through Children's Hospital of Wisconsin)
Role:
Co-PI
Dates:
2011 - 2012
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Regional
1. Kelly M, Schindler J, Polyamine biosynthesis and embryonal carcinoma cell differentiation, 8th Annual Regional Graduate Student Symposium - Platform Presentation, Case Western Reserve University, Cleveland, OH, 1984
2. Kelly M, Schindler J, A possible role of polyamines in embryonal carcinoma cell differentiation, Midwest Regional Developmental Biology Meeting - Poster Presentation, Xavier University, Cincinnati, OH, 1984
3. Kelly M., CBC abnormalities; when to refer. A hematologist’s perspective, Southeast Missouri Pediatric Society, Cape Girardeau, MO, 2003
4. Kelly M., Assessment and diagnosis of abdominal masses in children, Cardinal Glennon Children’s Hospital Pediatric CME Series, Saint Louis, MO, 2004
5. Kelly M., Biology and Treatment of Childhood Leukemias, Best Practices in Pediatrics, Deerfield, IL, 9/2006
6. Kelly M., Umbilical Cord Blood Stem Cells, Pediatric Grand Rounds, Milwaukee, WI, 11/2006
7. Kelly M., HPV Vaccination: Cancer Prevention to Culture Wars, Pediatric Grand Rounds, Milwaukee, WI, 12/2007
8. Kelly M., Post Transplant Lymphoproliferative Disease in Children, Solid Organ Transplant Grand Rounds, Milwaukee, WI, 3/2008
9. Kelly M., Acute Lymphoblastic Leukemia: Past Successes and Future Challenges, Best Practices in Pediatrics, Lake Geneva, WI, 9/2011
10. Kelly M., Pediatric Oncology, North Shore Kiwanis Presentation, Milwaukee, WI, 6/2012
 
National
1. Kelly M, Schindler J., Polyamine biosynthesis and embryonal carcinoma cell differentiation, 74th Annual Meeting of the American Society of Biological Chemists - Poster Presentation, San Francisco, CA, 1983
2. Kelly M, Schindler J, Polyamines and embryonal carcinoma cell differentiation, Gordon Conference on Polyamines - Poster Presentation, New Hampshire, 1985
3. Kelly M, Hayashi R, DeBaun MR., The role of chemotherapy in treatment of post-transplant lymphoproliferative disease, Pediatric Oncology Group National Meeting - Platform Presentation, Tampa, FL, 1999
4. Kelly M., Clinical Trials in Hemangiomas, 22nd annual meeting of the American Society of Pediatric Hematology and Oncology - Platform Presentation, San Diego, CA, 5/2008
5. Kelly M., Innovations in Vascular Anomalies, Pediatric Society of Otolaryngology - Panel Discussion, Miami, FL, 2008
 
International
1. Kelly M, McCarthy BM, Harmony JAK., Mitogen - dependent effects of apolipoprotein E on interleukin - 2 autoregulation of activated T lymphocytes, The 10th International Symposium on Drugs Affecting Lipid Metabolism - Platform Presentation, Houston, TX, 1989
2. Kelly M, Schauer D, Drolet BA, Grossman W., Immune Analyses in Children with Hemangiomas Treated with Steroids, 17th International Workshop on Vascular Anomalies, ISSVA - Platform Presentation, Boston, MA, 2008
3. Kelly M, Juern A, Duffy K, Drolet B., Vincristine is a safe and effective treatment for complicated infantile hemangiomas, 18th International Workshop on Vascular Anomalies, ISSVA, Brussels, Belgium, 2010
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. Kelly M, Schindler J, Polyamines and embryonal carcinoma cell differentiation, Gordon Research Conference on Polyamines - Poster Presentation, NH, 1983
2. Kelly M, Schindler J, Polyamine biosynthesis and embryonal carcinoma cell differentiation, 74th Annual Meeting of the American Society of Biological Chemists - Poster Presentation, San Francisco, CA, 1983
3. Kelly M, Hayashi R, DeBaun MR, The role of chemotherapy in treatment of post-transplant lymphoproliferative disease, Pediatric Oncology Group National Meeting - Platform Presentation, Tampa, FL, 1999
4. Shenoy S, Kelly M, Grossman W, Ramadas J, Musselman M, Rituximab therapy in children with chronic refractory immune cytopenias: long term efficacy and immune function analysis, American Society of Hematology (ASH) 33rd Annual Meeting, San Diego, CA, 12/2003
5. Rao A, Kelly M, Musselman M, Ramada J, Grossman W, Whitney J, Shenoy S, A Multi-Center Efficacy and Immune Analysis Trial of Rituximab for Refractory Pediatric Immune Cytopenia, American Society of Hematology/Oncology (ASPHO) 19th Annual Meeting - Poster Presentation, San Francisco, CA, 5/2006
6. Shenoy S, DeBaun M, Rao Arati, Kelly M, Barnes Y, Yu Lolie, Allogeneic Transplantation in Children with Sickle Cell Anemia and Beta Thalassemia Using a Reduced Intensity Conditioning Regimen, American Society of Hematology/Oncology (ASPHO) 19th Annual Meeting - Presentation, San Francisco, CA, 5/2006
7. Duffy KJ, Kelly M, Drolet BA, Lesion specific expression changes in a patient with Proteus syndrome: Potential implications for the P13K/AKT pathway, Society of Investigative Dermatology Annual Conference, Phoenix, AZ, 5/2011
 
International
1. Kelly M, McCarthy BM, Harmony JAK, Mitogen - dependent effects of apolipoprotein E on interleukin - 2 autoregulation of activated T lymphocytes, 10th International Symposium on Drugs Affecting Lipid Metabolism - Platform Presentation, Houston, TX, 1989
2. Kelly M, Schauer D, Drolet BA, Grossman W, Immune Analyses in Children with Hemangiomas Treated with Steroids, 17th International Workshop on Vascular Anomalies, ISSVA - Platform Presentation, Boston, MA, 2008
3. Maronn M, Catrine K, North PE, Browning M, Kerschner J, Drolet BA, Kelly ME, Mulitfocal Lymphangioendotheliomatosis with Thrombocytopenia, International Society for Vascular Anomalies Annual Meeting, Boston, MA, 2008
4. Kelly M, Juern A, Duffy K, Drolet B, Vincristine is a safe and effective treatment for complicated infantile hemangiomas, 18th International Workshop on Vascular Anomalies, ISSVA, Brussels, Belgium, 2010
 
COMMITTEE SERVICE:
Medical College
6/2010 - 11/2011 Member, Search Committee for Section Chief and MACC Fund Professor, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
1/2011 - Present Member, Cancer Center Leadership Committee, Medical College of Wisconsin
 
MEDICAL COLLEGE TEACHING ACTIVITIES:
Continuing Medical Education
9/2006 Best Practices in Pediatrics Sponsored by Children's Specialty Group and Children's Hospital of Wisconsin - Biology and Treatment of Childhood Leukemias
11/2006 Pediatric Grand Rounds Presentation - Umbilical Cord Blood Stem Cells
12/2007 Pediatric Grand Rounds Presentation - HPV Vaccination: Cancer Prevention to Culture Wars
3/2008 Solid Organ Transplant Grand Rounds Presentation - Post Transplant Lymphoproliferative Disease in Children
9/2011 Best Practices in Pediatrics Sponsored by Children's Specialty Group and Children's Hospital of Wisconsin - Acute Lymphoblastic Leukemia: Past Successes and Future Challenges
 

BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Schindler J, Kelly M, McCann PP. Inhibition of ornithine decarboxylase induces embryonal carcinoma cell differentiation. Biochem Biophys Res Commun. 1983 Jul 18;114(1):410-7
2. Schindler J, Kelly M, McCann PP. The response of several murine embryonal carcinoma cell lines to stimulation of differentiation by alpha-difluoromethylornithine. J Cell Physiol. 1985 Jan;122(1):1-6
3. Kelly M, McCann PP, Schindler J. Alterations in polyamine metabolism during embryonal carcinoma cell differentiation in vitro. Dev Biol. 1985 Oct;111(2):510-4
4. Uhl L, Kelly M, Schindler J. alpha-Difluoromethylornithine induces differentiation of a human embryonal carcinoma cell line in vitro. Biochem Biophys Res Commun. 1986 Oct 15;140(1):66-73
5. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol. 1994 Dec;159(2):124-39
6. Mistry MJ, Clay MA, Kelly ME, Steiner MA, Harmony JA. Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol. 1995 Jan;160(1):14-23
7. Cohen AH, Sweet SC, Mendeloff E, Mallory GB Jr, Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1252-5
8. Pickhardt PJ, Siegel MJ, Hayashi RJ, Kelly M. Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. Radiology. 2000 Oct;217(1):16-25
9. Blaeser F, Kelly M, Siegrist K, Storch GA, Buller RS, Whitlock J, Truong N, Chatila TA. Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. Clin Immunol. 2005 Dec;117(3):231-7
10. Knutsen A, Kelly ME, Wall DA. Umbilical Cord Blood Transplantation in Severe T-Cell Immunodeficiency Disorders. Pediatric Asthma, Allergy and Immunology. 2005;18:189-200
11. Broom MA, Wang LL, Otta SK, Knutsen AP, Siegfried E, Batanian JR, Kelly ME, Shah M. Successful umbilical cord blood stem cell transplantation in a patient with Rothmund-Thomson syndrome and combined immunodeficiency. Clin Genet. 2006 Apr;69(4):337-43
12. Lai JS, Cella D, Kupst MJ, Holm S, Kelly ME, Bode RK, Goldman S. Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). J Pediatr Hematol Oncol. 2007 Jul;29(7):471-9
13. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008 Apr;50(4):822-5
14. Cameron C, Greenbaum L, Sato T, Trost B, Lundeen B, Kelly ME. Renal cell carcinoma in a patient with cystinosis and inflammatory bowel disease: a case report. Pediatr Nephrol. 2008 Jul;23(7):1167-70
15. Maronn M, Catrine K, North P, Browning MB, Kerschner JE, Noel R, Drolet BA, Kelly M. Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer. 2009 Apr;52(4):531-4
16. Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol. 2010 Jul;146(7):767-74
17. Smart DR, Taintor AR, Kelly ME, Lyon VB, Segura A, Jensen JN, Drolet BA. Microcystic adnexal carcinoma: the first reported congenital case. Pediatr Dermatol. 2011 Jan-Feb;28(1):35-8
18. Noel RJ, Duffy KJ, Kelly ME, Tondravi N, North PE, Drolet BA. Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications. J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):822-4
19. Drolet BA, Trenor CC, Brandão, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, North P, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. [Accepted 2013 Jan].
20. Petersen CL, Hemker BG, Jacobson RD, Warwick AB, Jaradeh SS & Kelly ME. Wilms’ Tumor Presenting with Lambert-Eaton Myasthenic Syndrome. Pediatrics. 2013 [Accepted with revisions].
21. Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2012 Nov;59(5):934-8
22. Kelly ME, Xiaomin L, Devidas M, Abshire T, Bernstein ML, Billet A, Homas A, Mandell L, Ogeden A, Sandler E, & Buchanan G. Treatment of Relapsed Non-T, Non-B Acute Lymphoblastic Leukemia with Intensive Chemotherapy: POG (Pediatric Oncology Group) Study 9411 (SIMAL 9). J Pediatr Hematol Oncol. 2013 [Submitted].
 
Books, Chapters, and Reviews
1. Schindler J, Kelly ME. Retinoids, polyamines and teratocarcinoma differentiation in Meyskens and Prasad, (eds) Vitamins and Cancer - Human Cancer Prevention by Vitamins and Micronutrients. The Humana Press Inc.; 1985: 19-33
2. Hayashi R, Pickhardt PJ, Siegel MJ, Kelly ME. Post-transplant lymphoproliferative disease in children: clinical, histopathologic, and imaging features in Radiology. 2000:217;16-25
3. Kelly M, Chan A. The central role for the B cell linker protein BLNK in coordinating signals in the pre-BCR and BCR signaling pathways in Current Opinions in Immunology. 12th ed. 2000: 267-275
4. Kelly M. Kasabach-Merritt phenomenon in Drolet & Garzon (eds) Pediatr Clin North Am. Elsevier Inc.; 2010:57(5):1085-9
5. Kelly ME, Adams, S. Vascular Neoplasms in Rudolph and Rudolph (eds), Rudolph's Pediatrics. 22nd ed. New York, NY: McGraw-Hill; 2011: Ch. 462
6. Duffy K, Kelly ME, Bick D. Vascular Overgrowth in North and Sander (eds) Vascular Tumors and Developmental Malformations: Pathogenic Mechanisms, Diagnosis, and Clinical Management. Human Press/Springer; 2011: In Press
 
Abstracts
1. Schindler J, Kelly M. Polyamine biosynthesis and embryonal carcinoma cell differentiation. Federation Proceedings. 1983;42:2053
2. Kelly M, Schindler J. Inhibition of ornithine decarboxylase activity induces differentiation in embryonal carcinoma cells. Anatomical Record. 1983:205:96A
3. Schindler J, Kelly M. Polyamines and embryonal carcinoma cell differentiation. Federation Proceedings. 1984:43:1890
4. Schindler J, Uhl L, Kelly M. Transglutaminase activity and embryonal carcinoma cell differentiation. Journal of Cell Biology. 1985:101:110A
5. Mistry MJ, Kelly M, Harmony JAK. Apolipoprotein E (ApoE) regulates the proliferation of interleukin 2 (IL2) - dependent T lymphocytes. FASEB Journal. 1992:6:A371
6. Shenoy S, Kelly M, Grossman W, Ramada J, Musselman M. Rituximab therapy in children with chronic refractory immune cytopenias: long term efficacy and immune function analysis. Blood (American Society of Hematology Meeting Abstracts). 2003 Nov 16; 102(11): #1020
7. Shenoy S, DeBaun M, Rao Arati, Kelly M, Barnes Y, Yu Lolie. Allogeneic Transplantation in Children with Sickle Cell Anemia and Beta Thalassemia Using a Reduced Intensity Conditioning Regimen. Pediatr Blood Cancer. 2006 May 15; 46(6):698
8. Rao A, Kelly M, Musselman M, Ramada J, Grossman W, Whitney J, Shenoy S. A Multi-Center Efficacy and Immune Analysis Trial of Rituximab for Refractory Pediatric Immune Cytopenia. Pediatr Blood Cancer. 2006 May 15; 46(6):693
9. Kelly, M, McCarthy BM, and Harmony JAK. 1989. Mitogen - dependent effects of ApoE on IL-2 autoregulation of activated T lymphocytes. The 10th International Symposium on Drugs Affecting Lipid Metabolism, Houston, TX.
10. Maronn, M, Catrine K, North P, Browning M, Kerschner J, Drolet BA, Kelly M. 2008. Multifocal Lymphangioendotheliomatosis with Thrombocytopenia. 2008. ISSVA.
 
Non-Peer Reviewed Educational Products
1. Kelly ME, PhD Thesis, Apolipoprotein E inhibits interleukin 2 production and interleukin 2 receptor expression by mitogen stimulated T lymphocytes invitro, 1995